Method for measuring proteoglycan

The method of cleaving disulfide bonds and modifying thiol groups under alkaline conditions allows for the detection of intact C-terminal and N-terminal domains in proteoglycans, addressing the issue of domain cleavage in existing extraction methods and enhancing their evaluation for regenerative medicine.

WO2024232423A1PCT designated stage expired Publication Date: 2024-11-14ICHIMARU PHARCOS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017331
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-07
Filing Date
2024-05-10
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for extracting proteoglycans often result in the cleavage of the C-terminal and/or N-terminal domains, making it difficult to evaluate the presence or absence of these domains, which is crucial for their potential use in regenerative medicine.

Method used

A method involving the cleavage of disulfide bonds, modification of thiol groups under alkaline conditions, and fluorescence detection to maintain and detect the C-terminal and N-terminal domains of proteoglycans, allowing for their accurate measurement.

Benefits of technology

Enables the detection of proteoglycans with intact C-terminus and N-terminus, reducing the number of samples needed and improving the assessment of proteoglycan integrity, which is vital for regenerative medicine applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017331_14112024_PF_FP_ABST
    Figure JP2024017331_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a method for measuring a proteoglycan capable of detecting a proteoglycan in which the C-terminus and / or the N-terminus are maintained. A method for measuring a proteoglycan according to the present disclosure includes: a cutting step for cutting a disulfide bond in the proteoglycan; a modification step for modifying thiol groups in the obtained proteoglycan under alkaline conditions; and a detection step for detecting at least one of the C-terminal domain and the N-terminal domain of the proteoglycan by fluorescence.
Need to check novelty before this filing date? Find Prior Art

Description

Proteoglycan measurement method

[0001] The present disclosure relates to a method for measuring proteoglycans.

[0002] Proteoglycans are molecules that constitute the extracellular matrix together with collagen, hyaluronic acid, etc. In recent years, purification of proteoglycans by extraction with guanidine hydrochloride, extraction with acetic acid, etc. has been reported (Patent Document 1 and Non-Patent Document 1).

[0003] Patent No. 3731150

[0004] Kakizaki I, Tatara Y, Majima M, Kato Y, Endo M. Identification of proteoglycan from nasal salmon cartilage. Arch Biochem Biophys. 2011 Feb 1;506(1):58-65. doi: 10.1016 / j.abb.2010.10.025. Epub 2010 Nov 5. PMID: 21056541.

[0005] The proteoglycan exists in the body in a state bound to hyaluronic acid, etc. Therefore, proteoglycans in a state capable of binding to hyaluronic acid, etc., may potentially be used in regenerative medicine. However, depending on the extraction method, the proteoglycan may be extracted in a state in which the C-terminal domain (hereinafter also referred to as the "C-terminus") and / or the N-terminal domain (hereinafter also referred to as the "N-terminus") of the proteoglycan is cleaved. For this reason, it is necessary to evaluate the state of the proteoglycan, more specifically, the presence or absence of the C-terminus and / or N-terminus of the proteoglycan.

[0006] Therefore, an object of the present disclosure is to provide, for example, a method for measuring proteoglycans that can detect proteoglycans with the C-terminus and / or N-terminus maintained.

[0007] In order to achieve the above-mentioned object, the method for measuring proteoglycans (hereinafter also referred to as "measurement method") of the present disclosure includes a cleavage step of cleaving disulfide bonds of the proteoglycan, a modification step of modifying thiol groups of the obtained proteoglycan under alkaline conditions, and a detection step of detecting at least one of the C-terminal domain and the N-terminal domain of the proteoglycan by fluorescence.

[0008] According to the present disclosure, for example, it is possible to provide a method for measuring proteoglycans that can detect proteoglycans with the C-terminus and / or N-terminus maintained.

[0009] FIG. 1 is a diagram showing the main disaccharide structure of each chondroitin sulfate. FIG. 2 is a diagram showing the structures of various proteoglycans. FIG. 3 is a photograph showing the results of detecting the C-terminal domain of proteoglycan in Example 1. FIG. 4 is a photograph showing the results of detecting the N-terminal domain of proteoglycan in Example 1. FIG. 5 is a photograph showing the results of detecting the C-terminal domain of proteoglycan in Example 1. FIG. 6 is a photograph showing the results of detecting the C-terminal domain of proteoglycan in Example 2. FIG. 7 is a photograph showing the results of detecting decorin in Example 3.

[0010] The present disclosure will be specifically described below using examples. Unless otherwise specified, each disclosure may incorporate the explanations of other disclosures.

[0011] <Definition> As used herein, "proteoglycan" refers to a molecule (glycoprotein) in which a protein (core protein) and a glycosaminoglycan (GAG, also called "polysaccharide" or "sugar chain") are covalently bonded. The proteoglycan exists as an extracellular matrix in, for example, skin, organs, and cartilage. The glycosaminoglycan is generally known as a sugar chain having a long chain structure without a branched structure. Examples of the proteoglycan include the following: Aggrecan family (also called the lectican family or hyalectan family): aggrecan, versican, neurocan, brevican, etc. - Small leucine rich proteoglycans (SLRPs) family: biglycan, decorin, fibromodulin, lumican, PG-Lb (epiphycan), keratocan, mimecan, etc. - Basement membrane proteoglycans: perlecan, agrin, permacan, etc. - Others: testican, biglycan, serglycin, syndecan, dystroglycan, claustrin, glypican, keratocan, etc. The proteoglycans can also be classified into chondroitin sulfate proteoglycans, dermatan sulfate proteoglycans, heparan sulfate proteoglycans, and keratan sulfate proteoglycans, depending on the type of GAG bound to the protein.

[0012] Examples of the GAG ​​include chondroitin, chondroitin sulfate (CS), dermatan sulfate (DS, chondroitin sulfate B), heparan sulfate, heparin, and keratan sulfate. Examples of the chondroitin include an O-type sugar chain whose main disaccharide structure is a disaccharide structure of glucuronic acid and acetylgalactosamine, and an iO-type sugar chain whose main structure is a disaccharide structure of iduronic acid and acetylgalactosamine (hereinafter also referred to as "chondroitin sulfate O" and "chondroitin sulfate iO," respectively). The chondroitin sulfate (CS) has a structure in which a sulfate group is added to a sugar chain in which the disaccharide structure of glucuronic acid and acetylgalactosamine is repeated. Examples of the chondroitin sulfate include chondroitin sulfate A (type A), whose main disaccharide structure is a disaccharide structure of glucuronic acid and acetylgalactosamine tetrasulfate, and chondroitin sulfate C (type C), whose main disaccharide structure is a disaccharide structure of glucuronic acid and acetylgalactosamine hexasulfate. Dermatan sulfate (DS) has a structure in which a sulfate group is added to a sugar chain in which the disaccharide structure of iduronic acid and acetylgalactosamine is repeated. Examples of the dermatan sulfate include chondroitin sulfate iA (type iA), whose main disaccharide structure is a disaccharide structure of iduronic acid and acetylgalactosamine tetrasulfate, and chondroitin sulfate iC (type iC), whose main disaccharide structure is a disaccharide structure of iduronic acid and acetylgalactosamine hexasulfate. Each chondroitin sulfate has, for example, the disaccharide structure shown in FIG. 1 as its main disaccharide structure. In FIG. 1, the sulfate group (sulfo group) is bonded to a hydrogen atom, but the present disclosure is not limited to this. For example, the sulfate group of the GAG ​​may be ionized by eliminating the hydrogen atom, or may form a salt.

[0013] As used herein, the term "domain" refers to a region in a protein that is structurally or functionally integrated. Examples of structures containing the domains of aggrecan, versican, neurocan, brevican, and decorin are shown in Figure 2.

[0014] As used herein, the term "N-terminal domain (N-terminus)" refers to, for example, the G1 domain, IGD domain (interglobular domain), G2 domain, and / or KS-rich domain of a proteoglycan when the proteoglycan is a lectican family proteoglycan such as aggrecan. For example, when the proteoglycan is a small leucine-rich proteoglycan such as decorin, the term "N-terminal domain" refers to the domain N-terminal to the leucine-rich repeat domain of the proteoglycan. The G1 domain is known to bind to hyaluronic acid, link protein, and the like. When the proteoglycan is decorin, the N-terminal domain has chondroitin sulfate or dermatan sulfate in its side chain and four cysteine ​​residues.

[0015] As used herein, the term "C-terminal domain (C-terminus)" refers to the C-terminal domain containing the G3 domain of a proteoglycan, for example, when the proteoglycan is a lectican family proteoglycan such as aggrecan. For example, when the proteoglycan is a small leucine-rich proteoglycan such as decorin, the term "C-terminal domain" refers to the domain C-terminal to the leucine-rich repeat domain of the proteoglycan. The G3 domain is known to bind to tenascin and the like. When the proteoglycan is decorin, the C-terminal domain has two cysteine ​​residues.

[0016] As used herein, the term "intermediate domain" refers to a domain between the N-terminal domain and the C-terminal domain of a proteoglycan, which includes at least one glycosaminoglycan-binding domain (GAG), for example, when the proteoglycan is a lectican family proteoglycan. For example, when the proteoglycan is a small leucine-rich proteoglycan such as decorin, the term "intermediate domain" refers to a domain between the N-terminal domain and the C-terminal domain of the proteoglycan, which includes a leucine-rich repeat.

[0017] As used herein, "alkaline" refers to an aqueous solution having a pH greater than 7. As used herein, aqueous solutions of interest are classified as acidic, neutral, and alkaline when their pH is less than 7, 7, and greater than 7, respectively.

[0018] As used herein, the term "disulfide bond" (S--S bond) refers to a bond between sulfur atoms formed between two thiol groups (--SH).

[0019] As used herein, the term "reducing agent" refers to a substance that can reduce (donate electrons to) another substance in an oxidation-reduction reaction.

[0020] As used herein, the term "modification" refers to chemical modification of a specific functional group of an amino acid residue or the like that constitutes a protein.

[0021] In this specification, "alkylation" refers to converting a hydrogen atom constituting an organic compound into an alkyl group (C n H 2n+1 The substance that causes this alkylation is called an alkylating agent.

[0022] As used herein, "purified" means identifying and separating, recovering from components in their natural state, being identified and separated, and / or recovered from components in their natural state. The "purification" can be carried out, for example, by obtaining at least one purification step. The purification can also be referred to as isolation.

[0023] As used herein, "extraction" refers to the extraction of a specific component from a subject and / or the state in which a specific component has been extracted from a subject. The extraction can be performed, for example, using an extraction liquid such as a solvent. The "extraction" can be performed, for example, by performing at least one extraction process. As used herein, a substance containing a component extracted from a subject is referred to as an extract. Furthermore, a liquid containing a component extracted from a subject is referred to as an extract. The extract and the extract may contain, for example, the proteoglycan. The extract or the extract may contain, for example, components other than the proteoglycan derived from the animal tissue used for the extraction (other components). Examples of the other components include lipids, nucleic acids, proteins, etc.

[0024] The present disclosure will be described below using examples, but the present disclosure is not limited to the following examples and can be implemented with any modifications. Furthermore, the descriptions in this disclosure and each embodiment can be mutually incorporated unless otherwise specified. In this specification, when the expression "~" is used, it is used to mean including the numerical or physical values ​​before and after it. In addition, in this specification, the expression "A and / or B" includes "A only," "B only," and "both A and B."

[0025] <Method for Measuring Proteoglycans> In one aspect, the present disclosure provides a method for measuring proteoglycans. The method includes a cleavage step of cleaving disulfide bonds in proteoglycans, a modification step of modifying thiol groups in the resulting proteoglycans under alkaline conditions, and a detection step of detecting at least one of the C-terminal domain and the N-terminal domain of the proteoglycans by fluorescence. The method of the present disclosure can detect proteoglycans with their C-terminus and / or N-terminus maintained. Furthermore, the method of the present disclosure can simultaneously measure the N-terminus and C-terminus of the proteoglycans, thereby reducing the number of proteoglycan samples used for measurement, for example.

[0026] As a result of extensive research, the present inventors have found that proteoglycans are extracted with their C-terminus and / or N-terminus maintained or cleaved, depending on the type of extractant, etc. Further research led the present inventors to discover that the C-terminus and / or N-terminus of proteoglycans can be detected by fluorescence detection by cleaving the disulfide bonds of purified proteoglycans and modifying the thiol groups of the proteoglycans under alkaline conditions, thereby inhibiting the formation of complexes between the proteoglycans and hyaluronic acid, etc. Thus, the present disclosure has been established. Therefore, the measurement method of the present disclosure can detect proteoglycans with their C-terminus and / or N-terminus maintained.

[0027] In the cleavage step, disulfide bonds of the proteoglycan are cleaved. As a result, for example, the three-dimensional structure of the proteoglycan can be disrupted in the cleavage step, and when the proteoglycan has a C-terminus and / or an N-terminus, the complex formed between the proteoglycan and the hyaluronic acid or the like can be dissolved. Therefore, when the proteoglycan has a C-terminus and / or an N-terminus, the cleavage step can expose the C-terminus and / or the N-terminus of the proteoglycan, i.e., make them detectable.

[0028] The cleavage step can be carried out, for example, in a reaction system (cleavage system) containing the proteoglycan and a component capable of cleaving disulfide bonds in the proteoglycan. The cleavage system is, for example, a liquid system such as an aqueous solution. Specifically, in the cleavage step, the proteoglycan is contacted with a component capable of cleaving disulfide bonds, thereby cleaving disulfide bonds present in the proteoglycan. The contact of the proteoglycan with the component capable of cleaving disulfide bonds can be carried out, for example, by a known method for contacting a solid with a liquid, specifically by mixing the proteoglycan with a solution containing the component capable of cleaving disulfide bonds.

[0029] An example of the component capable of cleaving disulfide bonds is a reducing agent. When the reducing agent is used in the cleavage step, the cleavage can also be referred to as reduction to thiol groups by the reducing agent. The reducing agent is not particularly limited, and is, for example, a compound capable of reducing disulfide bonds to free thiol groups. Examples of the reducing agent include dithiothreitol (DL-dithiothreitol, DTT), β-mercaptoethanol (BME), tris(2-carboxyethyl)phosphine (TCEP), and glutathione.

[0030] The cleavage conditions (temperature, time, etc.) in the cleavage step are not particularly limited and can be set, for example, under conditions that allow the disulfide bond to be sufficiently cleaved into the thiol group. The cleavage conditions can be appropriately set, for example, depending on the type of the reducing agent, etc. The reaction temperature in the cleavage is, for example, preferably 45 to 100°C, more preferably 50 to 60°C. The reaction time in the cleavage is, for example, preferably 3 minutes to 6 hours, more preferably 5 minutes to 3 hours.

[0031] The proteoglycan may be, for example, an animal-derived proteoglycan. The animal is not particularly limited, and examples thereof include fish such as salmonids (e.g., chum salmon, Atlantic salmon) and flatfish (e.g., platypus), avian animals (birds) (e.g., chicken), and mammalian animals (mammals) (e.g., pig). The animal is preferably salmon, chicken, pig, or flatfish.

[0032] The proteoglycan may be derived from a tissue containing proteoglycan. Examples of the tissue include epithelial tissue such as skin; cartilaginous tissue such as cartilage; digestive organs; circulatory organs; respiratory organs; and placenta. Specific examples of the tissue include cartilage, fins, digestive organs, circulatory organs, respiratory organs, and ears.

[0033] Examples of the sugar chain of the proteoglycan include chondroitin, chondroitin sulfate, dermatan sulfate (chondroitin sulfate B), heparan sulfate, heparin, and keratan sulfate. The sugar chain is preferably chondroitin sulfate.

[0034] The proteoglycan used in the measurement method of the present disclosure may be self-prepared or commercially available. In the former case, the measurement method of the present disclosure may include, for example, a step of extracting and / or purifying proteoglycan from an animal or animal tissue prior to the cleavage step. When using self-prepared proteoglycan, the proteoglycan may be proteoglycan purified by acetic acid extraction or proteoglycan purified by guanidine extraction. When performing acetic acid extraction, proteoglycan can be purified with reference to the method described in Japanese Patent No. 3731150. When performing guanidine extraction, proteoglycan can be purified with reference to the methods described in References 1 and 2 below. Reference 1: Kakizaki I, Tatara Y, Majima M, Kato Y, Endo M. Identification of proteoglycan from salmon nasal cartilage. Arch Biochem Biophys. 2011 Feb 1;506(1):58-65. doi: 10.1016 / j.abb.2010.10.025. Epub 2010 Nov 5. PMID: 21056541. Reference 2: Kakizaki I, Mineta T, Sasaki M, Tatara Y, Makino E, Kato Y. Biochemical and atomic force microscopic characterization of salmon nasal cartilage proteoglycan. Carbohydr Polym. 2014 Mar 15;103:538-49. doi: 10.1016 / j.carbpol.2013.12.083. Epub 2014 Jan 7. Erratum in: Carbohydr Polym. 2015 Jan 22;115:805. PMID: 24528764.

[0035] The molecular weight of the proteoglycan may be measured before the cleavage step. The molecular weight of the proteoglycan refers to the peak top molecular weight measured by GPC (Gel Permeation Chromatography). The molecular weight of the proteoglycan can be measured using GPC or the like. The GPC method can be performed, for example, under the following conditions, and the standard samples (molecular weight markers, pullulan) are individually injected into an HPLC system to obtain a molecular weight calibration curve, thereby allowing calculation.

[0036] (Conditions for measuring peak top molecular weight (Mp)) HPLC system: LC-20AD (Shimadzu Corporation) Column: TSKgel G5000-PWXL φ7.8 mm×300 mm (Tosoh Corporation) Eluent: pH 6.8 phosphate buffer Flow rate: 0.5 mL / min Column temperature: 40° C. Detector: differential refractive index detector (RID-20A, Shimadzu Corporation) Injection volume: 50 μL Molecular weight marker: Shodex STANDARD P-82 (pullulan) The peak top molecular weight (Mp) and weight average molecular weight (Mw) / number average molecular weight (Mn) of the molecular weight marker are as follows: STD P-800: Mp: 739,000, Mw / Mn: 1.24 STD P-400: Mp: 348,000, Mw / Mn: 1.33 STD P-200: Mp: 216,000, Mw / Mn: 1.22 STD P-100: Mp: 107,000, Mw / Mn: 1.12 STD P-50: Mp: 49,400, Mw / Mn: 1.08 STD P-20: Mp: 22,000, Mw / Mn: 1.08 STD P-10: Mp: 9,800, Mw / Mn: 1.07 STD P-5: Mp: 6,300, Mw / Mn: 1.09

[0037] The peak top molecular weight of the proteoglycan subjected to the measurement is, for example, 300,000 to 1,300,000, or 400,000 to 1,200,000.

[0038] Next, in the modification step, the free thiol groups of the proteoglycan obtained in the cleavage step are modified under alkaline conditions. As a result, in the modification step, for example, the free thiol groups of the proteoglycan are modified, and the reformation of disulfide bonds between thiol groups can be inhibited. Therefore, in the case where the proteoglycan has a C-terminus and / or an N-terminus, the modification step can maintain the C-terminus and / or the N-terminus of the proteoglycan in an exposed state, i.e., a detectable state. Therefore, in the measurement method of the present disclosure, the modification step can maintain the C-terminus and / or the N-terminus of the proteoglycan in a detectable state, thereby enabling the detection of the C-terminus and / or the N-terminus in the detection step described below.

[0039] The modification step can be carried out in a reaction system (modification system) containing the proteoglycan obtained in the cleavage step and a modifying agent used for the modification. The reaction system is, for example, a liquid system such as an aqueous solution. The reaction system can be prepared by mixing the proteoglycan and the modifying agent.

[0040] The modification step is preferably carried out under alkaline conditions. The pH in the modification step (modification pH) is, for example, preferably pH 7.5 to pH 8.5, and more preferably pH 7.8 to pH 8.2. By carrying out the modification step at, for example, pH 7.5 or higher, the thiol groups can be suitably modified, thereby enabling the C-terminus and / or N-terminus of the proteoglycan to be suitably detected. In the modification step, the pH of the reaction system can be adjusted using, for example, an alkali such as sodium hydroxide, potassium hydroxide, potassium hydroxide, sodium bicarbonate, or sodium borate; or an acid such as hydrochloric acid, sulfuric acid, nitric acid, citric acid, or phosphoric acid.

[0041] Examples of the modification include chemical modifications such as alkylation, glutathionylation, sulfonation, sulfenation or sulfination, and nitrosation (nitrosylation). The modification can be carried out, for example, by using a modifying agent (reactant) containing a modifying group to be imparted by the modification. Specific examples of the alkylation can be carried out using an alkylating agent. The alkylating agent is, for example, a compound capable of reacting with the thiol group to alkylate the thiol group. Examples of the alkylating agent include organic iodide salts such as iodoacetamide, methyl iodide, and iodoacetic acid, and alkylene oxides such as ethylene oxide. The alkylating agent may be used alone or in combination. The sulfenation or sulfination can be carried out, for example, using a compound capable of oxidizing the thiol group. Examples of the compound capable of oxidizing the thiol group include oxidizing agents. The nitrosation can be carried out using, for example, a compound capable of donating nitric oxide (NO), specifically, S-nitrosoglutathione.

[0042] The modification conditions (temperature, time, etc.) in the modification step are not particularly limited and can be set, for example, under conditions that allow the thiol group to be sufficiently modified. The reaction temperature in the modification is, for example, preferably 15 to 40° C. The reaction time in the modification is, for example, preferably 5 minutes or more, more preferably 5 minutes to 16 hours.

[0043] In the modification step, the modification may include, for example, components other than the modifying agent. Examples of the other components include a buffering agent such as a buffer, a pH adjusting agent, and the like.

[0044] The measurement method of the present disclosure may optionally include, after the modification step and prior to the detection step, a solid-phasing step of solidifying the proteoglycan on a carrier such as a substrate. The solid-phasing method can be carried out by, for example, a known method for solidifying proteins, specifically, a covalent bond method, an ionic bond method, a physical adsorption method, a hydrophobic interaction method, or the like.

[0045] Examples of the carrier include plates such as microwell plates, microarray substrates, membranes (e.g., polyvinylidene fluoride (PVDF) membranes, nitrocellulose membranes, polystyrene nonwoven fabrics, etc.), and low-fluorescence carriers (e.g., low-fluorescence plates, low-fluorescence membranes, etc.).

[0046] In the measurement method of the present disclosure, for example, after the solid-phase immobilization step, the carrier may be blocked to prevent nonspecific binding of components such as antibodies used in the detection step described below. Examples of blocking agents used for blocking include albumin such as bovine serum albumin (BSA), skim milk, and commercially available blocking reagents.

[0047] Next, in the detection step, at least one of the C-terminal domain and the N-terminal domain of the modified proteoglycan is detected by fluorescence. This allows the detection step to detect, for example, the presence or absence of the C-terminus and / or the N-terminus of the proteoglycan. Specifically, the detection method can be carried out by contacting the modified proteoglycan with a probe and detecting the probe bound to the proteoglycan by fluorescence. The detection may be carried out by immobilizing the probe or proteoglycan on a substrate or the like.

[0048] In the detection step, either one or both of the C-terminal domain and the N-terminal domain of the modified proteoglycan may be detected. In the latter case, it is preferable that, for example, the C-terminal domain and the N-terminal domain of the proteoglycan are detected simultaneously by fluorescence in the detection step.

[0049] Examples of the N-terminal domain of the proteoglycan to be detected include the G1 domain, the IGD domain, and the G2 domain, and preferably the G1 domain. The detection may involve detecting, for example, one, two, or three of the N-terminal domains. Examples of the C-terminal domain of the proteoglycan to be detected include the G3 domain.

[0050] The detection can be carried out, for example, by fluorescent detection of the target component, specifically by immunoassay. Examples of the immunoassay include a direct method in which binding between a probe and a proteoglycan is detected; an indirect method in which a first probe is bound to a proteoglycan and then a second probe is used to detect the first probe bound to the proteoglycan; a sandwich method in which a first probe is bound to a proteoglycan and then a second probe is used to detect the proteoglycan bound to the first probe; Western blotting, immunoprecipitation, and immunohistochemical staining. The immunoassay can be quantitative or qualitative.

[0051] Examples of the probe include target-specific proteins such as polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments; target-specific nucleic acid molecules such as aptamers; etc. The antibody may be an antibody of any isotype of immunoglobulin selected from, for example, IgG, IgM, IgA, IgD, IgE, and IgY. The antibody fragment may be, for example, F(ab') 2 , antibody fragments such as Fab', Fab, and Fv.

[0052] The probe may be, for example, labeled. Specific examples of the antibody include, for example, an antibody labeled for detection. Examples of the label include a fluorescent dye label, an enzyme label, and a radioactive label. When the fluorescence detection is performed by a direct method, the probe is preferably, for example, a fluorescently labeled probe. When the fluorescence detection is performed by an indirect method, the second probe is preferably, for example, a fluorescently labeled probe.

[0053] The fluorescence detection can be carried out, for example, using a fluorescence detector.

[0054] Next, examples of the present disclosure will be described. However, the present disclosure is not limited to the following examples. Commercially available reagents were used according to their protocols unless otherwise specified. Note that "mol / l" may also be abbreviated as "M."

[0055] Example 1 The measurement method of the present disclosure was able to detect the C-terminus and N-terminus of proteoglycan.

[0056] (1) Purification of proteoglycans by guanidine extraction. 100-150 g each of chum salmon nasal cartilage, chicken sternal cartilage, porcine bronchial cartilage, and golden flounder fin were prepared as raw materials. A 5-fold (w / v) volume of 4 M guanidine hydrochloride aqueous solution was added to the raw materials. After the addition, immersion extraction was performed at 4°C for one week. After the extraction, filtration was performed using a 60-mesh sieve and filter paper (3 μm). After filtration, a 3-fold (v / v) volume of ethanol was added. After the addition, the mixture was left to stand overnight at 4°C. After the standing, filtration was performed using filter paper (3 μm), and the precipitate was recovered. After the recovery, phosphate buffer (pH 6.8) was added to dissolve the precipitate. After the dissolution, fractionation and purification were performed using a molecular weight cutoff membrane (MW 50,000, manufactured by Asahi Kasei Corporation). After the fractionation and purification, the proteoglycan fraction was collected. After the collection, the proteoglycan fraction was freeze-dried to obtain proteoglycan by guanidine extraction.

[0057] (2) Purification of proteoglycan by acetic acid extraction 100 to 150 g of nasal cartilage from chum salmon was prepared as a raw material. Purification of proteoglycan by acetic acid extraction was carried out with reference to the method described in Reference 1 below. Proteoglycan by acetic acid extraction was obtained by this purification. Reference 1: Japanese Patent No. 6317053

[0058] (3) Detection of the C-terminal domain of proteoglycan derived from chum salmon nasal cartilage. The C-terminal domain of proteoglycan extracted with guanidine and that extracted with acetic acid, obtained in Example 1(1) or Example 1(2), were detected. Specifically, 0.1 ml of PBS (pH 8.0) containing 20 mmol / L dithiothreitol (DTT) was added to 20 μg of each of the proteoglycans derived from chum salmon nasal cartilage. After the addition, the mixture was allowed to stand for 10 minutes to cleave disulfide bonds. After the cleavage, 40 mmol / L iodoacetamide was added, and alkylation was carried out for 30 minutes at pH 8.0. After alkylation, 10 μl, 50 μl, or 100 μl of the proteoglycan (0.5 mg / ml; hereafter, the same concentration is used for immobilization) or 50 μl of 0.5 mg / ml BSA (control) was immobilized on a membrane. The immobilization (hydrophobic interaction) was performed using BioDot (BioRad) and a low-fluorescence PVDF membrane (Immobilon-FL membrane, Merck). After immobilization, a 1:1000 diluted primary antibody (anti-aggrecan G3 domain antibody, Anti-Aggrecan Antibody clone 1-C-6, MABT84, Merck) was added, and the primary reaction was carried out at 4°C for 16 hours. After the primary reaction, the membrane was washed with TBS (Tris buffer) containing 0.05% Tween-20. After washing, a secondary antibody (goat anti-mouse IgG StarBright Blue 700, 12004159, BioRad) diluted 1 / 2500 was added, and the secondary reaction was carried out at 25°C for 1 hour. After the secondary reaction, fluorescence was detected using a multiplex fluorescence detector (ChemiDoc Touch MP, BioRad). The results are shown in Figure 3. In the comparative example (non-reduced), C-terminus detection was carried out in the same manner, except that disulfide bond cleavage and alkylation were not performed.

[0059] Figure 3 is a photograph showing the results of detecting the C-terminal domain in proteoglycans. The upper panel of Figure 3 shows the results when disulfide bond cleavage and alkylation were performed, while the lower panel of Figure 3 shows the results when disulfide bond cleavage and alkylation were not performed. In Figure 3, "light" indicates 10 μl of each proteoglycan, "medium" indicates 50 μl of each proteoglycan, and "high" indicates 100 μl of each proteoglycan. As shown in Figure 3, when disulfide bond cleavage and alkylation were not performed, the C-terminal domain signal was weakly detected in all samples, regardless of extraction method. On the other hand, when disulfide bond cleavage and alkylation were performed in proteoglycans extracted with acetic acid, the C-terminal domain signal was strongly detected. Furthermore, when disulfide bond cleavage and alkylation were performed in proteoglycans extracted with guanidine, the signal was weaker than in proteoglycans extracted with acetic acid, but the C-terminal domain signal was still detectable. These results demonstrate that the C-terminal domains of proteoglycans extracted with guanidine and proteoglycans extracted with acetic acid are preserved by using the measurement method of the present invention.

[0060] (4) Detection of N-Terminal Domains of Various Proteoglycans The N-terminal domains of the guanidine-extracted proteoglycans and the acetic acid-extracted proteoglycans obtained in Example 1(1) or Example 1(2) were detected. Specifically, the proteoglycans used were proteoglycan derived from chum salmon nasal cartilage, proteoglycan derived from chicken sternal cartilage, proteoglycan derived from porcine bronchial cartilage, or proteoglycan derived from the fin of Japanese flounder. 10 μl or 50 μl of the proteoglycan was used for immobilization. The primary antibody was an anti-aggrecan IGD domain antibody (Aggrecan Antibody, DF7561, epitope: V355-V375, Affinity Biosciences) diluted 1 / 1000, and the secondary antibody was a goat anti-rabbit IgG StarBright Blue 700 (12004162, BioRad) diluted 1 / 2500. Detection was performed in the same manner as in Example 1(3). These results are shown in Figure 4.

[0061] Figure 4 is a photograph showing the results of detecting the N-terminal domain in proteoglycans. The upper panel (low concentration) of Figure 4 shows the results for 10 μl of each proteoglycan, and the lower panel (high concentration) of Figure 4 shows the results for 50 μl of each proteoglycan. As shown in Figure 4, the N-terminal domain was not detected in the proteoglycan derived from chum salmon nasal cartilage extracted with acetic acid. On the other hand, the N-terminal domain was detected in the proteoglycan derived from chum salmon nasal cartilage, chicken sternal cartilage, porcine bronchial cartilage, and Japanese flounder fin, all of which were extracted with guanidine. These results demonstrate that, by using the measurement method of the present invention, the N-terminus is not preserved in the proteoglycan derived from chum salmon nasal cartilage extracted with acetic acid, whereas the N-terminal domain is preserved in the proteoglycans derived from various animals extracted with guanidine.

[0062] (5) Detection of C-terminal domains of various proteoglycans The C-terminal domains of proteoglycans extracted with guanidine and those extracted with acetic acid obtained in Example 1(1) or Example 1(2) were detected. Specifically, the detection was carried out in the same manner as in Example 1(3), except that the proteoglycans used were derived from chum salmon nasal cartilage, chicken sternal cartilage, or pig bronchial cartilage, and 10 μl or 50 μl of the proteoglycan was used for immobilization. These results are shown in FIG. 5.

[0063] Figure 5 is a photograph showing the results of detecting the C-terminal domain in proteoglycans. The upper panel of Figure 5 shows the results for 10 μl of each proteoglycan, and the lower panel of Figure 5 shows the results for 50 μl of each proteoglycan. As shown in Figure 5, the C-terminal domain was detected in the acetic acid-extracted proteoglycan derived from chum salmon nasal cartilage, as well as the guanidine-extracted proteoglycan derived from chum salmon nasal cartilage, chicken sternal cartilage, and porcine bronchial cartilage. These results demonstrate that the C-terminal domain is preserved in the acetic acid-extracted proteoglycan derived from chum salmon nasal cartilage and the guanidine-extracted proteoglycans derived from various animals by using the measurement method of the present invention.

[0064] (6) Detection of Various Domains of Various Proteoglycans The proteoglycans obtained in Example 1(1) or 1(2) by guanidine extraction and the various domains of the proteoglycans obtained by acetic acid extraction were detected. The various domains were N-terminal domain 1 (epitope: Val20-Gly675, G1-IGD-G2 domain), N-terminal domain 2 (epitope: aa50-150, G1 domain), C-terminal domain 1 (epitope: aa2358-2481, G3 Lectin-BD domain), and C-terminal domain 2 (epitope: aa2255-2280). Specifically, detection was performed in the same manner as in Example 1(3), except that antibodies capable of detecting the various domains were used as the primary antibodies and the secondary antibodies were antibodies capable of detecting the primary antibodies.

[0065] The primary antibodies are shown in Table 1 below. The primary antibody used to detect the N-terminal domain 1 was diluted 500-fold, the primary antibody used to detect the N-terminal domain 2 was diluted 900-fold, the primary antibody used to detect the C-terminal domain 1 was diluted 30-fold, and the primary antibody used to detect the C-terminal domain 2 was diluted 100-fold.

[0066] The secondary antibody used was goat anti-rabbit IgG StarBright Blue 700 (12004162, BioRad) diluted 1 / 2500 or goat anti-mouse IgG StarBright Blue 700 (12004159, BioRad) diluted 1 / 2500.

[0067]

[0068] In proteoglycans derived from chum salmon nasal cartilage extracted with acetic acid, the N-terminal domain was barely detected, and a portion of the G3 C-terminal domain was detected, but the lectin domain was not. In proteoglycans derived from chum salmon nasal cartilage, chicken sternal cartilage, and pig bronchial cartilage extracted with guanidine, all N-terminal domains were detected, and all G3 C-terminal domains were detected. These results demonstrate that, by using the measurement method of the present invention, only the C-terminal G3 domain is preserved in proteoglycans derived from chum salmon nasal cartilage extracted with acetic acid, and all N-terminal domains and all C-terminal G3 domains are preserved in proteoglycans derived from various animals extracted with guanidine.

[0069] Example 2 The C-terminus and N-terminus of proteoglycan could be detected by the measurement method of the present disclosure.

[0070] (1) Detection of Various Domains of Various Proteoglycans Various domains were detected in the proteoglycan (sCSPG-Gdm) derived from chum salmon nasal cartilage by guanidine extraction obtained in Example 1(1), the proteoglycan (sCSPG-AcOH) derived from chum salmon nasal cartilage by acetic acid extraction obtained in Example 1(2), the proteoglycan (cCSPG) derived from chicken sternal cartilage by guanidine extraction obtained in Example 1(1), and the proteoglycan (pCSPG) derived from porcine bronchial cartilage by guanidine extraction obtained in Example 1(1). The various domains were the G1 domain, IGD domain, G1-IGD-G2 domain, G3 domain 1, G3 domain 2 (epitope: aa2255-2280), and G3 lectin domain. Specifically, detection was performed in the same manner as in Example 1(3) above, except that antibodies capable of detecting the various domains described above were used as the primary antibodies and antibodies capable of detecting the primary antibodies were used as the secondary antibodies. The results are shown in Figure 6.

[0071] The primary antibodies are shown in Table 2 below. The primary antibody detecting the G1 domain was diluted 900-fold, the primary antibody detecting the IGD domain was diluted 1000-fold, the primary antibody detecting the G1-IGD-G2 domain was diluted 500-fold, the primary antibody detecting the G3 domain 1 was diluted 1000-fold, the primary antibody detecting the G3 domain 2 (epitope: aa2255-2280) was diluted 100-fold, and the primary antibody detecting the G3 lectin domain was diluted 30-fold.

[0072] The secondary antibody used was goat anti-rabbit IgG StarBright Blue 700 (12004162, BioRad) diluted 1 / 2500 or goat anti-mouse IgG StarBright Blue 700 (12004159, BioRad) diluted 1 / 2500.

[0073] Furthermore, the peak top molecular weights of the various proteoglycans were measured. Specifically, the various proteoglycans were subjected to HPLC analysis under the following measurement conditions. The results are shown in FIG. 6.

[0074] (HPLC measurement conditions) HPLC system: LC-10AD Column: TSKgel G5000-PWXL Φ7.8 mm × 300 mm (Tosoh Corporation) Eluent: pH 6.8 phosphate buffer solution Flow rate: 0.5 ml / min Column temperature: 40°C Detector: differential refractive index detector (RID-10A, Shimadzu Corporation) Injection volume: 50 μl Molecular weight marker: Shodex STANDARD P-82 (pullulan)

[0075]

[0076] Figure 6 is a photograph showing the results of detecting C-terminal domains in proteoglycans. From top to bottom, Figure 6 shows the results for the G1 domain, IGD domain, G1-IGD-G2 domain, G3 domain 1, G3 domain 2 (epitope: aa2255-2280), and G3 lectin domain. Also, from left to right, Figure 6 shows the results for BSA (1), acetic acid-extracted proteoglycan derived from chum salmon nasal cartilage (2) (sCSPG-AcOH), guanidine-extracted proteoglycan derived from chum salmon nasal cartilage (3) (sCSPG-Gdm), guanidine-extracted proteoglycan derived from chicken sternal cartilage (4) (cCSPG), and guanidine-extracted proteoglycan derived from porcine bronchial cartilage (5) (pCSPG). As shown in Figure 6, the N-terminal domain was barely detected in the acetic acid-extracted proteoglycan, but the C-terminal domain was detected in a portion of G3. On the other hand, both the N-terminal and C-terminal domains were detected in the acetic acid-extracted proteoglycan, the guanidine-extracted proteoglycan, cCSPG, and pCSPG. The peak top molecular weights of the acetic acid-extracted proteoglycan, the guanidine-extracted proteoglycan, cCSPG, and pCSPG were 480,000, 680,000, 630,000, and 640,000, respectively.

[0077] (2) Analysis of GAGs in Each Proteoglycan The various proteoglycans used in Example 2(1) were analyzed for GAGs. Specifically, GAGs were purified from the various proteoglycans used in Example 2(1). 10 g of the sCSPG-Gdm, cCSPG, or pCSPG was treated with 80 ml of boiling water for 10 minutes. After this treatment, 100 ml of 0.5 mol / L borate buffer (pH 7.0) was added. Then, 0.67 g of Protease N Amano G (Amano Enzyme) was added, followed by incubation at 55°C for 7 days. After this incubation, the mixture was quenched with 5% trichloroacetic acid. After quenching, insoluble matter was filtered and precipitated with 80% ethanol containing 1.25% NaOAc (sodium acetate). After the precipitation, the mixture was centrifuged at 0°C, and the resulting precipitate was dried in vacuo to obtain crude sugar chains. Next, 100 mg of the crude sugar chains was diluted with 0.05 mol / L acetic acid (pH 4.0) containing 0.15 mol / L LiCl. After the dilution, the crude sugar chains were applied to a DEAE-cellulose column (φ2.2 × 15 cm, Wako Pure Chemical Industries, Ltd.). After the application, the column was washed stepwise with 160 ml of buffer containing 0.15, 0.5, 1.0, or 2.0 mol / L LiCl. After the washing, the carbazole-positive fraction was collected and dialyzed, and the dialyzed sample was applied to a gel permeation column (LH-20, H 2 The GAG ​​was then desalted using a filter (φ1.1×80 cm) to obtain GAG. 2 After dilution, HPLC analysis was performed using a linearly coupled size exclusion column (OHpak SB-G 6B 100 x 4.6 mm and SB-805 HQ 250 x 4.6 mm).

[0078] (HPLC measurement conditions) HPLC system: LC-10AD (Shimadzu Corporation) Column: OHpak SB-G 6B 100 x 4.6 mm and SB-805 HQ 250 x 4.6 mm Eluent: 0.1 mol / l NaNO 3 Flow rate: 1mL / min

[0079] As a result, the peak top molecular weight (Mp) of guanidine-extracted GAG (sGAG) derived from chum salmon nasal cartilage was 84,000, the peak top molecular weight (Mp) of guanidine-extracted GAG (cGAG) derived from chicken sternal cartilage was 77,000, and the peak top molecular weight (Mp) of guanidine-extracted GAG (pGAG) derived from pig bronchial cartilage was 51,000.

[0080] (3) Disaccharide Structure in Each Proteoglycan The disaccharide structure of each proteoglycan was analyzed for the various GAGs obtained in Example 2(2). Specifically, 50 μg of each GAG obtained in Example 2(2) was added to 50 μl of H 2 The sample was diluted with 0.05 mg / 5 μl of BSA solution and 10 μl of 250 mmol / l Tris-HCl (AcOH) solution (pH 8.0). After dilution, the resulting diluted solution was digested with chondroitinase ABC (25 mU / 25 μl, Sigma-Aldrich) or chondroitinase AC (25 mU / 25 μl, Sigma-Aldrich) at 37°C or 30°C for 8 hours. After digestion, the unsaturated disaccharides produced by the digestion were subjected to HPLC analysis using a PA-03 (PA-G) column. In the analysis, the content (constituent ratio) of each disaccharide structure was calculated based on the HPLC peak area of ​​the standard unsaturated disaccharide. The results are shown in Table 3 below.

[0081]

[0082] As shown in Table 3, the contents of disaccharide structures were as follows: - Guanidine-extracted GAG derived from chum salmon nasal cartilage (sGAG) Chondroitin sulfate O: 11%, chondroitin sulfate iO: 0%, chondroitin sulfate A: 27%, chondroitin sulfate iA: 0%, chondroitin sulfate C: 61%, chondroitin sulfate iC: 0% - Guanidine-extracted GAG derived from chicken sternal cartilage (cGAG) Chondroitin sulfate O: 5.2%, chondroitin sulfate iO: 0%, chondroitin sulfate A: 63%, chondroitin sulfate iA: 6.5%, chondroitin sulfate C: 24%, chondroitin sulfate iC: 0.3% - Guanidine-extracted GAG derived from pig bronchial cartilage (pGAG) Chondroitin sulfate O: 6.1%, chondroitin sulfate iO: 0%, chondroitin sulfate A: 52%, chondroitin sulfate iA: 20%, chondroitin sulfate C: 19%, chondroitin sulfate iC: 2.1%

[0083] [Example 3] Next, we investigated whether decorin, a proteoglycan, could be detected instead of aggrecan by the measurement method of the present disclosure. Decorin is a small leucine-rich proteoglycan that has a single GAG ​​chain in its core protein.

[0084] First, bovine proteoglycan (dermatan sulfate proteoglycan: DSPG) was prepared. Approximately 824 g of the abomasum of a bovine (Holstein) was prepared as the raw material. The abomasum was washed and shredded into approximately 2 cm cubes while removing as much fat as possible. After shredding, a four-fold volume of ethanol (3288 ml) was added, and the mixture was allowed to stand for 10 minutes. This process was repeated once. Subsequently, a four-fold volume of ethanol (3288 ml) was added, and the mixture was allowed to stand overnight. After the standing, the ethanol was removed, and the mixture was air-dried. After air-drying, the mixture was dried under reduced pressure to obtain 173 g of a defatted, dried product. Next, the proteoglycan was purified from the defatted, dried product by guanidine extraction. Specifically, 87 g of the defatted, dried product of Example 2 (1-1) was added to 350 ml of a 4 M guanidine hydrochloride aqueous solution and subjected to immersion extraction at 4°C for 3 days. After the immersion extraction, 347 ml of a 4 M guanidine hydrochloride aqueous solution was added, and further immersion extraction was carried out at 4° C. for 3 days. After the immersion extraction, suction filtration and dialysis were carried out. After the dialysis, lyophilization was carried out to obtain 9.93 g of proteoglycan solids.

[0085] The proteoglycan was subjected to salt exchange with a neutral buffer solution (pH 7.5). Specifically, 60 ml of a neutral buffer solution (pH 7.5) was added to the bovine stomach-derived proteoglycan. After the addition, the mixture was sonicated and allowed to stand overnight. After the standing, the mixture was centrifuged to obtain a supernatant. The supernatant was then dialyzed and lyophilized.

[0086] Next, proteoglycans were reduced and alkylated using FOCUS Protein Reduction-Alkylation (786-231, G-Biosciences). 2.5 μl of Reductant Buffer was added to 500 μl of 1 mg / ml proteoglycan after salt exchange with the neutral buffer (pH 7.5) and stirred for 10 seconds. After stirring, 10 ml of FOCUS Protein Reductant was added and the mixture was left standing at 55°C for 1 hour. After leaving the mixture, 2.5 ml of Alkylation Buffer was added and stirred for 10 seconds. After stirring, 0.4 mol / L iodoacetamide was added and the mixture was left standing at room temperature (approximately 25°C) for 1 hour in the dark to alkylate the sample. Next, a PVDF membrane (Immobilon-FL membrane, Merck) was treated with methanol for 1 minute to hydrophilize it. After the hydrophilization, the PVDF membrane was immersed in TBS for 5 minutes. The PVDF membrane was then placed in a filtration blotting apparatus (BioRad). The alkylated sample was applied to the wells and aspirated. After the aspirate, the PVDF membrane was recovered from the filtration blotting apparatus and allowed to dry at room temperature. After the drying, the PVDF membrane was washed with TBS (Tris buffer, TBS-T) containing 0.05% Tween-20. After the washing, the PVDF membrane was blocked for 5 minutes using EveryBlot blocking buffer (BioRad). After blocking, a 1 / 1000-fold diluted primary antibody (anti-Decorin antibody, Cat No. 14667-1-AP, Proteintech) was added, and the primary reaction was carried out at 4°C for 18 hours. After the primary reaction, the membrane was washed five times with TBS-T for 5 minutes. After the washing, StarBright Blue (BioRad) diluted 1 / 2500 and 0.05% SDS were added, and the secondary reaction was carried out at room temperature for 1 hour. After the secondary reaction, the membrane was washed six times with TBS-T for 5 minutes. After the washing, the PVDF membrane was washed with ultrapure water and replaced with ultrapure water.After the substitution, the fluorescence of the PVDF membrane was detected using a multiplex fluorescence detector (ChemiDoc Touch MP, manufactured by BioRad.) The results are shown in FIG.

[0087] Figure 7 is a photograph showing the results of decorin detection. In Figure 7, the left column shows the results for BSA, and the right column shows the results for bovine-derived DSPG. As shown in Figure 7, a signal was detected in bovine-derived DSPG. These results demonstrate that decorin is preserved as a core protein in bovine proteoglycan that has been extracted with guanidine and salt-substituted with a neutral buffer (pH 7.5) using the measurement method of the present disclosure.

[0088] Although the present disclosure has been described above with reference to embodiments and examples, the present disclosure is not limited to the above embodiments and examples. Various modifications that can be understood by a person skilled in the art can be made to the configuration and details of the present disclosure within the scope of the present disclosure.

[0089] This application claims priority based on Japanese Patent Application No. 2023-078729, filed May 11, 2023, and Japanese Patent Application No. 2023-206830, filed December 7, 2023, the disclosures of which are incorporated herein in their entireties.

[0090] <Appendix> Some or all of the above embodiments and examples can be described as, but are not limited to, the following appendices. <Method for Measuring Proteoglycan> (Appendix 1) A method for measuring proteoglycan, comprising: a cleavage step of cleaving disulfide bonds of the proteoglycan; a modification step of modifying thiol groups of the resulting proteoglycan under alkaline conditions; and a detection step of fluorescently detecting at least one of the C-terminal domain and the N-terminal domain of the proteoglycan. (Appendix 2) The method according to Appendix 1, wherein the detection step involves simultaneously detecting the C-terminal domain and the N-terminal domain of the proteoglycan by fluorescence. (Appendix 3) The method according to Appendix 1 or 2, wherein the cleavage is reduction to thiol groups by a reducing agent. (Appendix 4) The method according to any one of Appendixes 1 to 3, wherein the alkaline condition is pH 7.5 to pH 8.5. (Appendix 5) The measurement method according to any one of Appendices 1 to 4, wherein the modification step inhibits disulfide bond formation by modifying the thiol group. (Appendix 6) The measurement method according to any one of Appendices 1 to 5, wherein the modification step involves alkylating the thiol group. (Appendix 7) The measurement method according to any one of Appendices 1 to 6, wherein a solid-phase step of solidifying the proteoglycan is carried out prior to the detection step. (Appendix 8) The measurement method according to any one of Appendices 1 to 7, wherein the N-terminal domain is a G1 domain, an IGD domain, and / or a G2 domain. (Appendix 9) The measurement method according to any one of Appendices 1 to 7, wherein the C-terminal domain is a G3 domain. (Appendix 10) The measurement method according to any one of Appendices 1 to 9, wherein the detection step involves detection by immunological assay. (Appendix 11) The measurement method according to any one of Appendices 1 to 10, wherein the peak top molecular weight of the proteoglycan is 400,000 to 1,200,000. (Supplementary Note 12) The measurement method according to any one of Supplementary Notes 1 to 11, wherein the proteoglycan is an animal-derived proteoglycan. (Supplementary Note 13) The measurement method according to Supplementary Note 12, wherein the proteoglycan is a proteoglycan of the lectican family. (Supplementary Note 14) The measurement method according to Supplementary Note 12 or 13, wherein the proteoglycan is aggrecan.(Appendix 15) The measurement method according to any one of Appendices 12 to 14, wherein the animal is selected from the group consisting of salmon, chicken, pig, and flounder.

[0091] As described above, the present disclosure can provide, for example, a method for measuring proteoglycans that can detect proteoglycans with their C-terminus and / or N-terminus maintained. Therefore, the present disclosure can be said to be extremely useful, for example, in the field of regenerative medicine.

Claims

1. A method for measuring proteoglycan, comprising: a cleavage step of cleaving disulfide bonds of the proteoglycan; a modification step of modifying thiol groups of the obtained proteoglycan under alkaline conditions; and a detection step of detecting at least one of the C-terminal domain and the N-terminal domain of the proteoglycan by fluorescence.

2. The method according to claim 1, wherein the detection step comprises simultaneously detecting the C-terminal domain and the N-terminal domain of the proteoglycan by fluorescence.

3. The method according to claim 1 or 2, wherein the cleavage is reduction to a thiol group by a reducing agent.

4. A measurement method described in any one of claims 1 to 3, wherein the alkalinity is pH 7.5 to pH 8.

5.

5. A measurement method described in any one of claims 1 to 4, wherein the modification step inhibits the formation of disulfide bonds by modifying the thiol groups.

6. A measurement method described in any one of claims 1 to 5, wherein in the modification step, the thiol group is alkylated.

7. A method according to any one of claims 1 to 6, further comprising a step of immobilizing the proteoglycan prior to the detection step.

8. A measurement method described in any one of claims 1 to 7, wherein the N-terminal domain is a G1 domain, an IGD domain, and / or a G2 domain.

9. A measurement method described in any one of claims 1 to 7, wherein the C-terminal domain is a G3 domain.

10. A method according to any one of claims 1 to 9, wherein the detection step is carried out by an immunological assay.

11. The method according to any one of claims 1 to 10, wherein the peak top molecular weight of the proteoglycan is 400,000 to 1,200,000.

12. The measurement method according to any one of claims 1 to 11, wherein the proteoglycan is an animal-derived proteoglycan.

13. The method according to claim 12, wherein the proteoglycan is a proteoglycan of the lectican family.

14. The method of claim 12 or 13, wherein the proteoglycan is aggrecan.

15. The method of any one of claims 12 to 14, wherein the animal is selected from the group consisting of salmon, chicken, pig, and flounder.

Citation Information

Patent Citations

  • Methods for preparing proteoglycan from animal cartilage

    JP2016160226A

  • Method for analyzing proteoglycan

    JP2018151206A

  • Method for measuring proteoglycan, method for evaluating proteoglycan, and measuring kit

    JP2020165937A

  • Apparatus for auto-pretreating sugar chain

    WO2009044900A1